{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:46:22Z","timestamp":1785901582784,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ebiom.2026.106351","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:57:14Z","timestamp":1782385034000},"page":"106351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A multi-centre, phase 1a\/1b dose escalation and expansion study of the HER2-directed antibody\u2013drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours"],"prefix":"10.1016","volume":"129","author":[{"given":"Herui","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4914-6508","authenticated-orcid":false,"given":"Meili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suiwen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuguo","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-9049","authenticated-orcid":false,"given":"Erwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2026.106351_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ebiom.2026.106351_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166384","article-title":"Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm","volume":"132","author":"Cobain","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2026.106351_bib3","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1158\/0008-5472.CAN-10-1529","article-title":"HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation","volume":"70","author":"Bollig-Fischer","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ebiom.2026.106351_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00345-016-1871-x","article-title":"HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.ebiom.2026.106351_bib5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ebiom.2026.106351_bib7","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update","volume":"40","author":"Giordano","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2026.106351_bib8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2026.106351_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ebiom.2026.106351_bib10","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2026.106351_bib11","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ebiom.2026.106351_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-025-07708-4","article-title":"A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2-positive unresectable LA\/MBC: final results of the ESTHER study","volume":"212","author":"Ring","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ebiom.2026.106351_bib13","doi-asserted-by":"crossref","first-page":"e13039","DOI":"10.1200\/JCO.2023.41.16_suppl.e13039","article-title":"A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer (aBC): interim results of the ESTHER study (NCT02393924)","volume":"41","author":"Harper-Wynne","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2026.106351_bib14","first-page":"480","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ebiom.2026.106351_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","article-title":"Epidemiology of triple-negative breast cancer: a review","volume":"27","author":"Howard","year":"2021","journal-title":"Cancer J"},{"key":"10.1016\/j.ebiom.2026.106351_bib16","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/curroncol28030168","article-title":"Current landscape of targeted therapy in hormone receptor-positive and HER2-negative breast cancer","volume":"28","author":"Andrahennadi","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ebiom.2026.106351_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ebiom.2026.106351_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ebiom.2026.106351_bib19","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/1538-7445.AM2023-2643","article-title":"Abstract 2643: BL-M07D1, a novel HER2-targeting ADC, demonstrates potent anti-tumor efficacy in preclinical pharmacodynamic models","volume":"83","author":"Wan","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ebiom.2026.106351_bib20","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1111\/cas.16234","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer","volume":"115","author":"Iwata","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ebiom.2026.106351_bib21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s12282-024-01600-7","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable\/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study","volume":"31","author":"Yamashita","year":"2024","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ebiom.2026.106351_bib22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2026.106351_bib23","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2026.106351_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426002343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:53:28Z","timestamp":1785898408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426002343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"alternative-id":["S2352396426002343"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106351","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multi-centre, phase 1a\/1b dose escalation and expansion study of the HER2-directed antibody\u2013drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106351"}}